Emory/Georgia TB Research Advancement Center (TRAC)

临床和人口科学核心（临床核心）的总体目标是加速数据驱动的 解决国内和全球结核病控制的持续挑战。为了实现这一目标，核心的战略 当务之急是通过促进新的合作和扩大现有的合作， 埃默里大学、格鲁吉亚（UGA）、 在格鲁吉亚和国际上的其他伙伴机构。 埃默里/格鲁吉亚TRAC的一个主要优势是我们长期的，富有成效的研究伙伴关系， 国际（埃塞俄比亚、乌干达、肯尼亚、南非、菲律宾和格鲁吉亚）和 国内研究中心（DeKalb和富尔顿县卫生委员会;美国疾病控制中心和 预防）。这些研究中心为不同的患者群体提供临床护理， 实验室和数据管理系统，并直接参与将研究转化为政策， 地方、国家和全球各级。临床核心教师是世界知名的结核病科学家， 在结核病/艾滋病毒、耐药结核病、结核病传播方面领先的有影响力的临床和流行病学研究记录， 儿童结核病、结核病/糖尿病和结核病后肺部健康。他们的尖端工作融合了创新 流行病学和生物统计学方法，以推进我们的结核病研究方法，包括地理空间 方法，网络分析，偏差分析，流行病建模和分子流行病学。这种粗放 研究组合还为研究人员提供了访问策展的研究数据库，组织的标本， 储存库和实地测试的研究工具。临床核心将利用这些资源和专业知识 使早期研究者能够进行科学严谨的多学科结核病研究， 建立了新的结核病研究人员。通过这种方式，核心将催化下一代结核病研究人员， 提高我们对结核病的认识，支持新兴科学的需求。 在三个综合目标中，临床核心将通过促进获得 在国际和国内临床研究中心，通过全面的 该计划将介绍，建立和培养TRAC调查人员之间的关系，我们的合作 合作伙伴，以及结核病新的早期和成熟的研究人员。核心将提供咨询， 通过端到端的方式，对从事结核病新的临床、流行病学或转化研究的研究人员进行培训， 最终支持研究规划、实施和传播。核心将开发一个集中的 与基础科学核心链接的研究数据和相关结核分枝杆菌分离株和标本库 生物库，为创新的临床和转化分析提供了许多机会。很长的- 核心的长期目标是培养一个强大的结核病临床研究环境， 合作扩大在TRAC内开展变革性研究的结核病研究人员的队伍。

The overarching goal of the Clinical & Population Science Core (Clinical Core) is to accelerate data-driven solutions to the persistent challenges of domestic and global TB control. To meet this goal, the Core’s strategic imperative is to promote innovative research on TB by fostering new collaborations and by expanding existing collaborations among scientists across diverse disciplines at Emory University, University of Georgia (UGA), other partner institutions in Georgia, and internationally. A major strength of the Emory/Georgia TRAC is our long-standing, productive research partnerships with both international (Ethiopia, Uganda, Kenya, South Africa, Philippines, and the country of Georgia) and domestic sites (DeKalb and Fulton County Boards of Health; U.S. Centers for Disease Control and Prevention). These research sites provide clinical care to diverse patient populations, have state-of-the-art laboratories and data management systems, and are directly engaged in translating research into policy at the local, national, and global levels. Clinical Core faculty are world-renowned TB scientists with successful track records of leading impactful clinical and epidemiologic research in TB/HIV, drug-resistant TB, TB transmission, pediatric TB, TB/diabetes, and post-TB lung health. Their cutting-edge work has integrated innovative epidemiologic and biostatistical methods to advance our approach to TB research, including geospatial methods, network analysis, bias analysis, epidemic modeling, and molecular epidemiology. This extensive research portfolio also provides investigators with access to curated research databases, organized specimen repositories, and field-tested study instruments. The Clinical Core will leverage these resources and expertise to enable the conduct of scientifically rigorous, multi-disciplinary TB research by early stage investigators and established investigators new to TB. In this way, the Core will catalyze the next generation of TB researchers, improve our understanding of TB, and support the needs of new and emerging science. In three integrated Aims, the Clinical Core will support high-impact research by facilitating access to diverse study populations at international and domestic clinical research sites through a comprehensive program that will introduce, establish, and nurture relationships between TRAC investigators, our collaborating partners, and early-stage and established investigators new to TB. The Core will provide consultation and training to investigators undertaking new clinical, epidemiologic, or translational research in TB through end-to- end support for study planning, implementation, and dissemination. The Core will develop a centralized repository of research data and associated Mtb isolates and specimens that links with the Basic Science Core biorepository, providing numerous opportunities for innovative clinical and translational analyses. The long- term goal of the Core is to cultivate a robust TB clinical research environment that is accessible, impactful, and collaborative to grow the pool of TB investigators conducting transformative research within the TRAC.